What Diater does

Diater is a privately held Spanish biopharmaceutical company founded in 1999 and headquartered in Leganés (Madrid), specializing in the development, manufacture, and commercialization of in vivo allergy diagnostics and allergen-specific immunotherapies. Its core product lines span skin prick tests, intradermal venom and beta-lactam antibiotic diagnostics, subcutaneous (SCIT) and sublingual (SLIT) immunotherapy, and a proprietary patented intradermal immunotherapy that uses fewer doses without adjuvants. Diater is a recognized pioneer in molecular immunotherapy based on purified native allergen proteins (Alt a 1 for Alternaria alternata, Cup a 1 for cypress pollen, Der p 1/Der p 2/Der p 23 for house dust mites) and was first to commercialize diagnostic methods for beta-lactam (penicillin) allergy aligned with EAACI guidelines. Underlying technology includes a vertically integrated GMP-compliant manufacturing footprint of three differentiated production units in Leganés totaling more than 4,000 sqm, plus Allergen Servilab (Ávila), which controls upstream raw allergen production including a dedicated mite cultivation unit. The My DIATER professional portal and Aula Digital Diater (ADD) e-learning campus provide the digital layer for healthcare professional engagement, ordering, and accredited CME.

The company's business model is B2B product sales to healthcare professionals (allergists, clinical immunologists, pediatric allergists) and specialized pharmaceutical distributors, with quote-based pricing and no public disclosure of unit economics. Diater maintains wholly-owned subsidiaries in Portugal (Laboratórios DIATER Lda., Lisbon metropolitan area) and Germany (DIATER Deutschland GmbH, Munich), and reaches more than 40 countries through an international network of over 200 specialized distributors. Revenue is supported by the recurring nature of multi-year (3–5 year) immunotherapy treatment cycles and the chronic prevalence of allergic disease. Diater was acquired in 2023 by WORG Pharmaceuticals, a Chinese clinical-stage strategic biopharmaceutical company focused on allergic and autoimmune disease, and now operates as a subsidiary of the WORG Group. Marketing is anchored in scientific thought leadership and recurring participation in European and Iberian allergy congresses (EAACI, SEICAP, SEAIC, SPAIC), combined with sponsor-branded accredited training programs and the DIATER-SEAIC Foundation Awards.

Name

Diater

Legal name

DIATER LABORATORIO DE DIAGNOSTICO Y APLICACIONES TERAPEUTICAS, S.A.

Website

https://diater.com

Company type

Private

Founded year

1999

Operating status

Acquired

Headcount range

101–250 employees

Short description

Diater is a Spanish biopharmaceutical company founded in 1999 that develops and manufactures allergy diagnostics and allergen-specific immunotherapies (including pioneering molecular immunotherapy with purified native allergens), selling B2B to allergists, immunologists, and pharmaceutical distributors in 40+ countries.

Ownership category

akta.pro rank

Product category

Allergy Biopharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Medicinal Chemicals & Botanical Products (2833), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Parasiticides & Ectoparasite Control (Flea/Tick/Heartworm) (HLAMAEAD)

akta.pro secondary industries

Government & Public-Sector Pharmaceutical Supply (Tender/Prime Vendor) (HLAIAJAF), Vaccines & Cold-Chain Pharmaceutical Distributors (HLAIAJAG)

Keywords

• Allergy diagnostics
• Molecular immunotherapy
• Allergen-specific treatment
• Biopharmaceutical manufacturing
• Sublingual immunotherapy

Headquarters

HQ city

Leganés

HQ country

Spain

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Biopharmaceutical product sales (diagnostics + immunotherapy): Core revenue stream from the development, manufacture, and sale of allergy diagnostics (skin prick tests, intradermal tests, beta-lactam allergy diagnostics) and allergen-specific immunotherapy products (subcutaneous, intradermal, sublingual). Products are sold B2B to healthcare professionals, hospitals, and specialized pharmaceutical distributors in 40+ countries, with recurring revenue driven by multi-year treatment cycles (3–5 year vaccination periods per patient) and the chronic, recurring nature of allergy management.
2. Subsidiary and distributor sales (international expansion): Revenue generated through wholly-owned subsidiaries (Spain, Portugal, Germany) and an extensive network of 200+ specialized distributors that facilitate access to DIATER's solutions for thousands of patients worldwide. This channel mix enables both direct margin capture in core markets and scalable geographic reach.
3. Continuing medical education and professional services (My DIATER): Supportive revenue/value stream via the "My DIATER" professional portal, Aula Digital Diater (ADD) e-learning campus, webinars, and accredited training programs (ALerMOLD, ITaMOLD, TIC Pediátrico). These programs drive product adoption and HCP loyalty, indirectly supporting primary product sales rather than generating standalone fees disclosed publicly.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels10 records

Core offering

Diater is a biopharmaceutical company that develops, manufactures, and sells allergy diagnostic products (skin prick tests, intradermal venom tests, beta-lactam allergy tests) and allergen-specific immunotherapy products (subcutaneous, intradermal, and sublingual formulations) based on purified native allergen proteins. Products are sold B2B to allergists, hospitals, and specialized pharmaceutical distributors in 40+ countries, primarily through wholly-owned subsidiaries in Spain, Portugal, and Germany and a network of 200+ international distributors.

Product overview

Diater operates a vertically integrated biopharmaceutical product portfolio rather than a single unified software product. Its core offering is divided into two main categories: (1) Diagnostic Products — including the Prick Test, Intradermal Venom Tests, and Beta-lactam Diagnostic Tests; and (2) Immunotherapy Products — comprising Subcutaneous Immunotherapy (SCIT) including molecular immunotherapy with purified native allergens (Alt a 1, Cup a 1, Der p 1, Der p 2, Der p 23), DIATER-developed patented Intradermal Immunotherapy, Sublingual Immunotherapy (SLIT), high-dose allergoid SCIT for polysensitized patients, and Hymenoptera venom immunotherapy. Underpinning these products is Allergen Servilab, the group's subsidiary that produces raw allergenic extracts (pollens, mites, fungi, venoms, animal epithelia). Diater also delivers the My DIATER professional portal and the Aula Digital Diater (ADD) educational platform, which serve as the digital layer for healthcare professionals to access the product catalog, place orders, and complete accredited training in allergy and immunology.

Differentiator

Problem solved

Functional benefit

Brands

• Diater Laboratories: Manufacturing arm of the DIATER Group dedicated to the production of biopharmaceutical products (diagnostics, vaccines and microbiological autovaccines).
• Allergen Servilab
• My DIATER

Products and services

• Prick Test (Skin Prick Test) Skin prick diagnostic test that introduces allergen extracts into the epidermis of the forearm via a lancet, read after 15-20 minutes using positive (histamine) and negative (saline) controls. The most widely used allergy diagnostic method due to high sensitivity and minimally invasive nature; used exclusively by healthcare professionals.
• Intradermal Venom Tests Intradermal skin tests more sensitive than prick testing, used when prick tests are negative but venom or drug allergy is suspected. Particularly used for diagnosis of drug and hymenoptera venom (bee/wasp) allergies, with results read 15-20 minutes after administration; administered by healthcare professionals.
• Beta-lactam Diagnostic Tests Validated diagnostic lines for detection of antibiotic allergies including beta-lactams (penicillin, clavulanic acid, amoxicillin). Includes prick tests, intradermal tests and controlled provocation tests performed by healthcare professionals following a step-up diagnostic strategy; aligned with EAACI guidelines.
• Subcutaneous Immunotherapy (SCIT) — Molecular Immunotherapy Monthly subcutaneous injections of the allergen(s) to which the patient is sensitized, administered by specialized healthcare professionals. Includes molecular immunotherapy based on purified native allergen proteins; initiation phase with weekly increasing doses and maintenance phase with dosing every 4 weeks over 3-5 years.
• Intradermal Immunotherapy (patented) Innovative intradermal immunotherapy developed and patented by Diater Laboratories. Requires fewer doses than conventional protocols, targets the immune system directly without adjuvants, and offers faster and more effective control of respiratory allergies.
• Sublingual Immunotherapy (SLIT) Sublingual immunotherapy administered daily by the patient at home under the tongue. Wide range of allergens available; generally well-tolerated with a favorable safety profile compared to SCIT for allergic rhinitis and asthma; used for polysensitized patients.
• High-dose Subcutaneous Immunotherapy with Allergoids Subcutaneous immunotherapy treatments with high-dose allergoids developed for polysensitized patients requiring adapted immunotherapy solutions.
• Hymenoptera Venom Immunotherapy (bee and wasp) Allergen-specific immunotherapy for bee and wasp venom allergies, manufactured using Diater's own optimized production process for hymenoptera venoms.
• Aula Digital Diater (ADD) Educational Platform Digital training campus for allergy and immunology specialists providing accredited courses endorsed by scientific societies, with on-demand webinars, tools, and resources on immunotherapy and management of allergic patients.

Quantifiable outcome

• Clinical improvement in 85% of patients receiving immunotherapy; effect maintained for up to 15 years after suspension of vaccination
• +2 more outcomes

Segments5 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Seven partnerships are on record, tiered core / industry membership, operational / sustainability, core / scientific endorsement, core / scientific endorsement (pediatric allergy), minor / certification body and core / compliance.

• Farmaindustria (Asociación Nacional Empresarial de la Industria Farmacéutica)core / industry membershipOthersDIATER is an associate member of Farmaindustria, the Spanish National Business Association of the Pharmaceutical Industry. Membership entails strict compliance with the Code of Good Practices of the Pharmaceutical Industry for promotion of medicines, interaction with healthcare professionals/patient organizations, and value-transfer transparency. Farmaindustria's Ethics Supervision Unit may receive identification and value-transfer data from DIATER based on the association's legitimate interest.
• SIGREoperational / sustainabilityOthersDIATER is a member of SIGRE, the Spanish entity responsible for ensuring proper environmental management of packaging and leftover medicines generated in households. The partnership enables correct recycling of DIATER pharmaceutical product waste and supports environmental awareness initiatives.
• SEAIC (Sociedad Española de Alergología e Inmunología Clínica) & SPAIC (Sociedade Portuguesa de Alergologia e Imunologia Clínica)core / scientific endorsementGTM or Marketing PartnerDIATER is a collaborating entity and recurring participant at joint SEAIC and SPAIC international congresses (e.g., 2nd SPAIC-SEAIC International Congress in Porto, April 2025). These congresses bring together allergology and clinical immunology specialists from Spain and Portugal for knowledge exchange, with DIATER sponsoring "Desayuno con el Experto" expert breakfast sessions and similar scientific activities.
• EAACI (European Academy of Allergy and Clinical Immunology)core / scientific endorsementGTM or Marketing PartnerDIATER participates annually in the EAACI Congress (e.g., EAACI 2025 in Glasgow with 7,000+ attendees from 100+ countries), maintaining an exhibition stand and engaging distributors, researchers, and institutional representatives from multiple countries. DIATER uses EAACI as a key venue to promote its molecular immunotherapy portfolio internationally.
• SEICAP (Sociedad Española de Inmunología Clínica, Alergología y Asma Pediátrica)core / scientific endorsement (pediatric allergy)GTM or Marketing PartnerDIATER is a recurring participant and "Desayuno con el Experto" sponsor at the SEICAP Congress (e.g., 49th SEICAP Congress in Santiago de Compostela, May 2025; 50th Congress SEICAP in 2026). Partnership focuses on pediatric allergy, including the 2nd edition of the TIC Pediátrico course accredited and endorsed by SEICAP.
• World Federation of Chambers of Commerce (WCF)minor / certification bodyOthersDIATER Laboratories is certified by the World Federation of Chambers of Commerce (WCF), a unique global network of 12,000 chambers of commerce from over 125 countries. The WCF certification is displayed on DIATER's website as a trust seal.
• Canal Ético external advisory team (Ethical Channel)core / complianceImplementation/ SI/ Consulting PartnerDIATER has contracted an external specialist advisory team to receive and process all communications through its Ethical Channel, strengthening confidentiality. The channel is operated through canaletico.com and [email protected] and is available to employees, collaborators, managers, clients, contractors, suppliers, and any third party.

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• LETI Pharma: Spanish allergy immunotherapy and diagnostics company, headquartered in Madrid. Most direct Spanish/Iberian peer to DIATER, with overlapping product categories and customer base (allergists, distributors).
• Allergy Therapeutics: UK-based allergy vaccine company developing both traditional and novel adjuvanted/SCIT products. Comparable as a mid-cap allergy immunotherapy specialist focused on disease-modifying vaccines for HCPs.
• Stallergenes Greer: French-American specialist in allergen immunotherapy and diagnostics. Closely comparable to DIATER in business model (diagnostics + immunotherapy, multi-modality SCIT/SLIT), serving allergists globally.
• HAL Allergy: Netherlands/Germany-based allergy diagnostics and immunotherapy company. Comparable mid-sized European specialist with overlapping product categories (skin prick diagnostics, SCIT, SLIT, venom immunotherapy).
• Roxall Medizin: German allergy diagnostics and immunotherapy manufacturer. Comparable mid-sized European allergy specialist with similar product categories and HCP-focused distribution.

Emerging players

• Circassia (now Aiolos Bio / transitioned assets): Historically a UK-based respiratory/allergy biopharma focused on novel immunotherapy. Comparable as a development-stage allergy immunotherapy player, though its commercial position has materially changed.
• Anergis: Swiss clinical-stage biopharma developing peptide-based allergy vaccines (contiguous overlapping peptide—COP). Comparable as a molecular/precision allergy immunotherapy developer targeting disease-modifying treatment.
• Biomay: Austrian biotech specializing in recombinant/molecular allergen production for diagnostics and immunotherapy. Comparable as a molecular allergen specialist; smaller scale and more R&D-stage than DIATER.

Broad incumbents

• ALK-Abelló: Danish global leader in allergy immunotherapy (SCIT, SLIT, diagnostics) with the broadest product portfolio and deepest R&D budget. Directly comparable as a molecular/extract-based allergy immunotherapy peer, but at materially larger scale and global commercial reach.

Regional players

• Immunotek: Spanish/Latin American allergy immunotherapy and vaccines manufacturer. Comparable product portfolio (diagnostics + immunotherapy), primarily focused on Latin American markets with overlap in Iberia.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/diater-laboratorios

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Diater